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Abstract  
The purpose of the current study is to approve or disprove the efficiency of the 
effectiveness comparing generic drugs and the respectively prototype drugs on 
lipid lowering agents based on two specific quality factors; first the thickness of 
the vessels' endothelium and second the calcification on vessels' walls. For the 
study drugs where recognized and divided into two categories: Unique drugs which 
included prototype drugs with protected exclusivity of the use of the active 
substance (on patent) according to the law. And generic drugs which NOM has 
given approvals as generic drugs. 
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Introduction 
The placement of generics from the 
edge of doubt to the center of 
acceptance (and moreover as equals to 
original medicines) was imposed by 
the state rationalizing expenses which 
was aimed at mitigating the distortion 
of the medicinal market during the 
current economic conjuncture 
(Gitonas, 2008). 
The legislation of a number of 
measures and interventions, as a result 
of the implementation of agreed 
financial and credit policy terms, led to 
the shrinking of the financial 
proliferation of the public insurance 
policy (WHO, 2013). Consequently, 
the comparison attempted in this study, 
between the effectiveness of the use of 
new hypolipidemic medicines on the 
one hand and of the equivalent long - 
distinguished medicines on the other 
hand, is necessary (Kyriopoulos, 
2014). 
Thus, two hundred and ninety six (296) 
samples of ascending aorta, left 
internal thoracic artery and right 
saphenous vein were created initially 
surgically and then using tissue from 
one hundred patients undergoing 
hypolipidemic treatment who were 
subjected to surgical treatment for 
coronary disease having an aorta - 
coronary by - pass. 
The results revealed a non - 
statistically important variation to the 
laboratory results of the hypolipidemic 
profile of patients to whom either 
generic or original medicines were 
administered, as well as to the tissue 
samples which confirmed the above 
findings. 
In conclusion: a) the infiltration of 
generic hypolipidemic medicines is 
significant in high sales rates, b) the 
reduction imposed on costs did not, in 
any occasion, result in the expected 
retention of expenses which, as they 
depend on price as well as demand, 
followed correspondingly the increase 
of D.D.D (Tang, 2017), c) the adoption 
of writing prescriptions based on the 
drastic substance had an effect on the 
limitation of the sales worth (Olivella, 
2017). 
 d) the hypolipidemic effectiveness of 
generic medicines was proven equal to 
that of original medicines as was 
revealed by the laboratory 
microbiological tests of patients as 
well as by the tissue samples of 
patients who had undergone heart 
surgery. 
 
Methodology 
From 98 patients with coronary 
disease, to whom lipid lower agents 
were given and they had a bypass, 
histological remainings of the inner 
thoracic artery, major saphenous vein, 
and ascending thoracic aorta were 
made. 
The taking of the fibrous material was 
made by the same surgical team. The 
histological study was made by a blind 
method so before the histological 
reading, so it will be impossible to 
correlate the findings with the kind of 
the given lipid lower agent or with the 
lab results from the clinic blood exams 
of the patient. 
Under general anesthesia a frontal 
thoracic section is made; before the 
section of the subcutaneous and the 
median sternotomy an assiduous 
.hemostasis is in order, so a clean 
surgical field will be ensured; the 
pericardium is cut and the coronary 
vessels- target are recognized; and the 
symmetric expander through the 
removal of semi-sternal parts is 
replaced with an asymmeter expander 
which puts pressure on the proximal 
and lifts the distal hemithorax. At the 
same time on the edge of the surgical 
cut on the inner surface of the thoracic 
wall the internal thoracic artery can be 
found. A strip of pleura is cut with 15 
cm length and 3 cm width which 
includes the internal thoracic artery (on 
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the subclavian of the inner part on the 
same height with the thyrocervical 
stem) until the point which is 
bifurcated (to the myofrenic artery and 
the upper epigastry artery). The 
internal thoracic artery is made, and its 
branches are tied securely peripheral 
end of the vessel, which is cut, is then 
used as a histological fiber. 
The major saphenous vein is found 
along and on the inner side of the tibia 
edge. The leading side of its beginning 
it is found in the middle of the distance 
between the inner side of the arthrosis 
between the leg and tarsus. Before the 
act of the main anastomosis and under 
the strict compliance of the hemostasis 
and embedding rules, the last part of 
the vessel is cut which will then be 
used as a histologic fiber. 
The act of the main anastomosis action 
on the ascending thoracic aorta it 
presupposes careful cut and rounding 
on the cut with special circle knife; the 
histological remainings of the walls, 
which comes from the round parts of 
the arcs which were cut from the knife, 
give the third pool of material which 
will be used as a histological fiber for 
the study. 
The procedure which was followed for 
the histological fibers which were used 
is briefly denoted below: 
 phase Ι. Fixation 
 phase ΙΙ. Embedding 
 phase ΙΙΙ. Sectioning in 
thin strips 
 phase IV. Staining and 
 phase V. Mounting on 
glass slides 
The microtome which was used on this 
specific study for the parafin slices was 
a Rotary Microtome HM340E of 
Thermo- Fischer Scientific Microm 
International GmbH. The observation 
of the histological parts was done on 
an optical microscope Zeiss, Axiostar 
Plus. For the photo shooting of the 
microscope images the camera which 
was used was a Zeiss AxioCam ERc 5s 
5 Megapixel Microscope Color 
Camera of Carl Zeiss Microscopy. The 
processing of the photographs and the 
measuring of the distance was done 
ZEN 2012 software (compatible with 
windows) from Zeiss. 
 
Results 
The examination of the damages on the 
vessels which were taken was made 
with microscopic examination of 
transverse and longitudinal sections. 
During the histopathological 
examination of the samples there 
where some alterations discovered 
which were evaluated based on two 
indicators – factors which were chosen 
based on the findings of the study and 
the most recent and accessible to us 
bibliography. Specifically, the first 
indicator which was evaluated was the 
width of the endothelium and 
especially from the inner layer until the 
inner membrane in at least 7 random 
points of the section with the same 
distance between them, so the mean of 
the endothelium width can be found. 
The recorded thickening of the 
endothelium until the point where the 
inner membrane is found is possibly 
explained on the deposition of fibrin or 
fibrous while in some cases during the 
deposition some collagen fibers were 
placed on the area. The measurement 
was made on at least two sections of 
different depth on the same vessel. The 
specific measurement was based on a 
scale and it was made using the 
identification key below: 
category 0: mean distance until the 
inner membrane <80μm 
category 1: mean distance until the 
inner membrane: 80-120 μm 
category 2: mean distance until the 
inner membrane: >120μm 
The results of the measurements are 
shown on the tables that follow both 
for the statin and fibrate according to 
the prototype or generic drug·(each 
category is followed by pictures  
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from characteristic histologic samples): 
 
Table 1.Number of patients which were 
given statin as prototype or generic drug 
according to the thickening of the inner 
layer 
STATIN 
categorization 
0 1 
 
No of patients for 
each category 
Patients which were given 
prototype drug 
8 3 
Patients which were given 
generic drug 
8 4 
 
Table 2. Number of patients which were 
given fibrate (for each category prototype 
or generic drug) according to the 
thickening of the inner layer 
FIBRATE 
categorization 
0 1 
 
Number of patients for each 
category 
Patients which were 
given prototype drug 
7 4 
Patients which were 
given generic drug 
9 7 
 
 
 
 
Figure 1: transverses section of inner 
thoracic artery · thickening of the 
endothelium which is made of loose 
connective tissue (between the arrows)·the 
inner membrane can be seen on the head 
of the left arrow. 
 
 
 
 
 
 
 
Figure 2: longitudinal cut of major 
saphenous vein: thickening of the 
endothelium (between the arrows) 
·the inner membrane can be seen on 
the head of the top left and on the 
bottom right arrow. 
 
 
Figure 3: accenting thoracic aorta: 
measurement of the width of the 
endothelium on 7 points (with same 
distance between them)·the width is 
denoted with the red lines. 
 
The second indicator which was 
evaluated was the presence of 
calcifications mainly around the layer. 
The calcifications are possibly 
connected with the previous focal or 
polyfocal necrosis or inflammation and 
incapability to remove the remainings 
which were created by these 
procedures. The specific deposition of 
calcium is possibly connected with the 
functional inadequacy of the vessel. 
The measurement is based on a scale 
and it is related to the number of 
calcifications which were observed.  
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About 2cm
2
 of tissue were examined 
from each vessel· so the samples are 
divided into 3 levels of importance 
according to the following 
identification key: 
category 0: no presence of 
calcification 
category 1: 1-2 calcifications in 
2 sections of different depth on the 
same vessel·sum of tissue area 2cm2 
category 2: >2 calcifications in 2 
sections of different depth on the same 
vessel·sum of tissue area 2cm2 
 
Table 3. Number of patients which were 
given statin, prototype or generic 
according to the presence of calcifications 
on the vessels of the walls. 
STATIN 
categorization 
0 1 
 
Number of patients in 
each category 
Patients which were given 
the prototype drug 
7 4 
Patients which were given 
the generic drug 
9 4 
 
Table 4. Number of patients which were 
given fibrate prototype or generic 
according with the presence of 
calcifications on the vessel of the wall. 
FIBRATE 
categorization 
0 1 
 
Number of patients in each 
category 
Patients which were 
given the prototype drug 
4 0 
Patients which were 
given the generic drug 
5 5 
 
 
Figure 4: inner thoracic artery: presence 
of small calcification (arrow)in the inner 
layer of the artery. 
 
 
Figure 5: inner thoracic artery: presence 
of multiple calcifications (green arrows) in 
the middle of the layer of the artery 
between the collagen fibers 
 
 
Figure 6: Inner thoracic artery: presence 
of calcifications (arrow) in the middle of 
the layer of the artery (between the 
collagen fibers) 
 
Ι, 1 
Variable under study (quantity, random 
variable): the endothelium width·level 
3: {0,1,2} 
Ssubstance: statin(it is examined if the 
activity of the substance is independent 
when prototype orgeneric drug is used) 
 
Table of observed measurements 
drug        
endothelium width 
Α Β 
0 8 8 
1 3 4 
2 2 3 
sum n01 = 13 n02 = 15 
Table of coherence on theoretical level 
drug      
endothelium width 
Α Β sum 
0 7,4 8,6 16,0 
1 3,3 3,7 7,0 
2 2,3 2,7 5,0 
sum 13,0 15,0 n = 28 
 
Because there are theoretical 
measurements smaller than 5, 
percentage 66.67% (>20%), we merge 
the 2 last lines (observed and 
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theoretical measurements) ·finally the 
table below comes up: 
 
drug  
endothelium width 
Α Β sum 
0 8/7,4 8/8,6 16 
“1+2” 5/5,6 7/6,4 12 
sum 13 15 n= 28 
 
Degrees of Freedom (D.F) = (2-1) (2-
1) = 1·1 = 1 
R = {χ2 >χ21, 0,05 = 3,84} 
Η0: the “drug” and “endothelium 
width” are independent variables 
Η1:theΗ0is rejected 
χ2 = 82/7,4 + 82/8,6 + 52/5,6 + 72/6,4 - 
28 = 1,182 (3,84) =>theΗ0is not 
rejected 
 
Ι, 2 
Variable under study (random 
variable): endothelium width 
Substance: fibrate (it is examined if the 
activity of the substance is depended 
according to the if the prototype drug 
is used (= Α)orgeneric (= Β)drug) 
 
Table of coherence on observed measurements 
drug  
endothelium width 
Α B sum 
0 7 9 n10 = 16 
1 4 7 n20 = 11 
2 0 1 n30 = 1 
sum n01=11 n02=17 n00= 28 
Table of coherence on theoretical measurements 
drug  
endothelium width 
Α Β 
0 6,3 9,7 
1 4,3 6,7 
2 0,4 0,6 
sum 11,0 17,0 
 
The sample is small because the 
theoretical measurements which are<5 
are more than 20%·merge of the two 
tables gives us the following table 
 
drug  
endothelium 
widthαααααααα 
Α Β sum 
0 7/6,3 9/9,7 16 
“1+2” 4/4,7 8/7,3 12 
sum 11 17 n = 28 
 
D.F = (2-1) (2-1) = 1·1 = 1 
R = {χ2 > χ21, 0,05 = 3,84} 
Η0: the variables “drug” και 
“endothelium width” are independent 
Η1:theΗ0is rejected 
Χ2 = 72/6,3 + 92/9,7 + 42/4,7 + 82/7,3 - 
28 = 0,300 (<3,84) =>theΗ0is not 
rejected 
 
ΙΙ, 1 
Variable under study (random 
variable): calcifications 
Substance: statin (it is examined if the 
activity of the substance is independent 
if the prototype (Α) orgeneric (Β) drug 
is used 
 
Table of coherence on theoretical measurements 
drugs  
calcifications 
Α Β 
0 7,1 8,9 
1 3,6 4,4 
2 1,3 1,7 
sum 12,0 15,0 
 
Table of coherence on observed measurements 
drugs  
calcificationsαααα 
Α Β 
0 7 9 
1 4 4 
2 1 2 
sum 12 15 
 
Because there are observed 
measurements <5 more than 20% we 
merge the 2 last lines·the following 
table comes up which includes both 
observed and theoretical measurements 
 
drugs 
 calcifications 
Α Β sum 
0 7/7,1 9/8,9 16 
“1+2” 5/4,9 6/6,1 11 
sum 12 15 n = 27 
 
D.F. = (2-1) (2-1) = 1·1 = 1 
R = {χ2 >χ21, 0,05 = 3,84} 
Η0: the variables “drugs” and 
“calcifications” are independent 
Η1:theΗ0is rejected 
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χ2 = 72/7,1 + 92/8,9 + 52/4,9 + 62/6,1 - 
27 = 0,006 (< 3,84) =>the Η0is not 
rejected 
 
ΙΙ,2 
Variable under study (random 
variable): calcifications 
Substance: fibrate (it is examined if the 
activity of the substance is independent 
from the use of prototype (Α) or 
generic(Β)drug 
 
Table of coherence on theoretical measurements 
drugs 
calcifications 
Α Β 
0 2,8 6,2 
1 1,6 3.4 
2 0,6 1,4 
sum 5,0 11,0 
Table of coherence on observed measurements 
drugs 
calcifications 
Α Β sum 
0 4 5 n10 = 9 
1 0 5 n20 = 5 
2 1 1 n30 = 2 
sum 5 11 n = 16 
 
The sample is small (Θ11, Θ21 and Θ22, 
only a theoretical measurement is 
larger than 5) because the results are 
on limit we merge the lines 1 and 2 in 
1+2 
 
drugs 
 calcifications 
Α Β sum 
0 4/2,8 5/6,2 9 
“1+2” 1/2,2 6/4,8 7 
sum 5 11 n = 16 
 
D.F. = (2-1) (2-1) = 1·1 = 1 
R = {χ2 > χ21, 0,05 = 3,84} 
Η0: the variables“drugs” and 
“calcifications” are independent 
Η1:the Η0 is rejected 
χ2 = 42/2,8 + 52/6,2 + 12/2,2 + 62/4,8 - 
16 = 1,701 (< 3,84) =>the Η0 is not 
rejected 
 
ΙΙΙ 
SHORT RESULT TABLE 
The variable active substance is 
controlled on 2 levels, ΑandΒ 
 
 statin fibrate 
endothelium 
width 
Χ2 = 1,182  
(< 3.84)  
(independent) 
Χ2 = 0,300  
(< 3.84) 
(independent) 
calcifications 
Χ2 = 0,006 
 (< 3.84) 
(interdependent) 
Χ2 = 1,701  
(< 3.84) 
(almost 
independent) 
 
General conclusion: For both 
substances: DRUG and BIOLOGICAL 
INDICATOR (endothelium width or 
calcifications) are independent 
variables 
 
Conclusion 
The study took place between 2004- 
2016 and it allowed the evaluation of 
the effect on medical substances, under 
common changes on the laws related 
with drugs.  
The distributions on the patient’s lipids 
were not different when given 
prototype or generic drug. 
The measurements are characteristic. 
There is not a statistical significant 
difference between generic and 
prototype drugs. Also, there is no 
significant difference between statin 
and fibrate. This happens since the pre-
surgical cardiological treatment of the 
patient gives the possibility for the 
personalization of the treatment for 
each patient so that the clinical 
phenotype will be the best as it comes 
from the lab profiles of the periodic 
check ups. 
The comparative study shows that 1st) 
the activity of the substance statin and 
the biological indicator endothelium 
width is an independent variable for 
both generic and prototype drugs· 2nd) 
the activity of the substance fibrate and 
the biological indictor endothelium 
width is an independent variable for 
both generic and prototype 
drugs·3rd)the activity of the substance 
statin and the indicator under study 
(random variable) calcification are 
independent, for both generic and 
prototype drugs·finally,4th)the activity 
of the substance fibrate when it comes 
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to the creation of calcifications on the 
endothelium is proved to be 
independent for both generic and 
prototype drugs. General conclusion: 
For both substances “SUBSTANCE 
and BIOLOGICAL VARIABLE 
(endothelium width and calcifications) 
are independent variables”. 
There was also observed that although 
there are ups and downs in general the 
population tends to increase the use of 
lipid lowering agents. 
Socioeconomic and demographic 
factors such as migration flows and the 
change of the age consistency, have in 
general increase the life expectancy to 
five years in the EE since 1990.Aging 
of the population leads to increase of 
needs from the Health Departments for 
long term health caring. In the middle 
of economic restrictions, it becomes a 
challenge to maintain a high quality 
pharmaceutical care for the total of the 
population. 
It is not to be underestimated the fact 
the evolution on biotechnology 
includes greater costs on research and 
larger cost on drugs, it puts a larger 
cost on public health insurance and it 
reduces the accessibility to the citizens. 
On the other hand, it is common that 
although a smaller dosage is necessary 
it still prescribed the former treatment. 
To sum up, the control first on the 
prescriptions and on the so-called 
abundance of the medicine and second 
on the chain of its trading, it is could 
consist a huge obstacle for newfound 
misperceptions.  
In any case, what is important is the 
clinical benefit directly depended on 
the category of the disease (e.g. orphan 
diseases), having also in mind the 
patient-target, as apriority, and shown 
on real measurements which are 
collected and compared impartially, 
due to the fact that this study 
contributes to the redefinition of the 
treatment value and making rational 
decisions when it comes to covering 
medical expenses and their most 
efficient good use.  
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